BCM-599

• Description :

  BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection[1].

• UNSPSC :

  12352005

• Target :

  Endogenous Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/bcm-599.html

• Smiles :

  FC1=CC=C(C=C1)C(NCC(NC2=C(N=C(C=C2)Cl)Cl)=O)=O

• Molecular Formula :

  C14H10Cl2FN3O2

• Molecular Weight :

  342.15

• References & Citations :

  [1]2-amino-N- (2,6-dichloropyridin-3-yl) acetamide derivatives as a novel class of HBV capsid assembly inhibitor

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1820763-99-2]